Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05724563 | Domvanalimab and Zimberelimab in Advanced Liver Cancers | PHASE2 | ACTIVE NOT_RECRUITING | 58 | — | — | Jun 1, 2023 | Jun 1, 2027 | May 21, 2025 | 1 | United States |
To determine the best objective response rate assessed by RECIST guidelines (version 1.1) of combination zimberelimab and domvanalimab in patients with advanced hepatobiliary cancers previously exposed to anti-PD-1/L1 antibody treatments.
| Arm | Type | Description |
|---|---|---|
| Zimberelimab and Domvanalimab | EXPERIMENTAL | Individual will be given Zimberelimab (AB122) 360 mg IV in a 1 hour infusion + 30 minute rest + Domvanalimab (AB154) 1200 mg IV in a 1 hour infusion every three weeks. Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason |
| Name | Type | Description |
|---|---|---|
| Zimberelimab | DRUG | Zimberelimab 360 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason. |
| Domvanalimab | DRUG | Domvanalimab 1200 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason. |
Inclusion Criteria: 1. Patient must have a histologically confirmed diagnosis consistent with HCC or bile duct cancer (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gall bladder cancers); known fibrolamellar HCC, or combined HCC-cholangiocarcinoma will be excluded....